



BASIC PHARMACOKINETICS AND PHARMACODYNAMICS



AN INTEGRATED TEXTBOOK AND COMPUTER SIMULATIONS



EDITED BY
SARA E. ROSENBAUM
SECOND EDITION



WILEY

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

An Integrated Textbook and Computer Simulations

Second Edition

Edited by

SARA E. ROSENBAUM

WILEY

Copyright © 2017 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Names: Rosenbaum, Sara (Sara E.), author, editor.

Title: Basic pharmacokinetics and pharmacodynamics : an integrated textbook and computer simulations / edited by Sara E. Rosenbaum.

Description: Second edition. | Hoboken, New Jersey : John Wiley & Sons, Inc., [2017] | Includes bibliographical references and index.

Identifiers: LCCN 2016031846 (print) | LCCN 2016034126 (ebook) | ISBN 9781119143154 (pbk.) |

ISBN 9781119143161 (pdf) | ISBN 9781119143185 (epub)

Subjects: | MESH: Pharmacokinetics | Pharmacological Phenomena | Computer Simulation

Classification: LCC RM301.5 (print) | LCC RM301.5 (ebook) | NLM QV 38 | DDC 615/.7—dc23

LC record available at <https://lccn.loc.gov/2016031846>

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

To Steve, Molly and Lucy

CONTENTS

Preface	xix
Contributors	xxi
1 Introduction to Pharmacokinetics and Pharmacodynamics	1
<i>Sara E. Rosenbaum</i>	
1.1 Introduction: Drugs and Doses, 2	
1.2 Introduction to Pharmacodynamics, 3	
1.2.1 Drug Effects at the Site of Action, 3	
1.2.2 Agonists, Antagonists, and Concentration–Response Relationships, 6	
1.3 Introduction to Pharmacokinetics, 9	
1.3.1 Plasma Concentration of Drugs, 9	
1.3.2 Processes in Pharmacokinetics, 11	
1.4 Dose–Response Relationships, 12	
1.5 Therapeutic Range, 14	
1.5.1 Determination of the Therapeutic Range, 15	
1.6 Summary, 18	
Reference, 18	
2 Passage of Drugs Through Membranes	19
<i>Sara E. Rosenbaum</i>	
2.1 Introduction, 20	
2.2 Structure and Properties of Membranes, 20	
2.3 Passive Diffusion, 21	
2.3.1 Transcellular Passive Diffusion, 23	
2.3.2 Paracellular Passive Diffusion, 25	
2.4 Carrier-Mediated Processes: Transport Proteins, 26	
2.4.1 Uptake Transporters: SLC Superfamily, 27	

- 2.4.2 Efflux Transporters: ABC Superfamily, 29
- 2.4.3 Characteristics of Transporter Systems, 31
- 2.4.4 Simulation Exercise, 32
- 2.4.5 Clinical Examples of Transporter Involvement in Drug Response, 32

References, 33

3 Drug Administration and Drug Absorption

35

Steven C. Sutton

- 3.1 Introduction: Local and Systemic Drug Administration, 36
 - 3.2 Routes of Drug Administration, 37
 - 3.2.1 Common Routes of Local Drug Administration, 37
 - 3.2.2 Common Routes of Systemic Drug Administration, 38
 - 3.3 Overview of Oral Absorption, 41
 - 3.3.1 Anatomy and Physiology of the Oral-Gastric-Intestinal Tract and Transit Time, 41
 - 3.4 Extent of Drug Absorption, 44
 - 3.4.1 Bioavailability Factor, 44
 - 3.4.2 Individual Bioavailability Factors, 45
 - 3.5 Determinants of the Fraction of the Dose Absorbed (F), 46
 - 3.5.1 Disintegration, 46
 - 3.5.2 Dissolution, 46
 - 3.5.3 Formulation Excipients, 50
 - 3.5.4 Adverse Events within the Gastrointestinal Lumen, 50
 - 3.5.5 Transcellular Passive Diffusion, 53
 - 3.5.6 Particulate Uptake, 53
 - 3.5.7 Paracellular Passive Diffusion, 53
 - 3.5.8 Uptake and Efflux Transporters, 54
 - 3.5.9 Presystemic Intestinal Metabolism or Extraction, 58
 - 3.5.10 Presystemic Hepatic Metabolism or Extraction, 60
 - 3.6 Factors Controlling the Rate of Drug Absorption, 61
 - 3.6.1 Dissolution-Controlled Absorption, 63
 - 3.6.2 Membrane Penetration-Controlled Absorption, 63
 - 3.6.3 Overall Rate of Drug Absorption, 63
 - 3.7 Biopharmaceutics Classification System, 64
 - 3.7.1 Intestinal Reserve Length, 64
 - 3.7.2 Biopharmaceutics Classification System (BCS), 64
 - 3.7.3 Biopharmaceutics Drug Disposition Classification System (BDDCS), 65
 - 3.8 Food Effects, 65
- Problems, 66
- References, 67

4 Drug Distribution

71

Sara E. Rosenbaum

- 4.1 Introduction, 72
- 4.2 Extent of Drug Distribution, 72
 - 4.2.1 Distribution Volumes, 74

- 4.2.2 Tissue Binding, Plasma Protein Binding, and Partitioning: Concentrating Effects, 75
- 4.2.3 Assessment of the Extent of Drug Distribution: Apparent Volume of Distribution, 76
- 4.2.4 Plasma Protein Binding, 82
- 4.3 Rate of Drug Distribution, 89
 - 4.3.1 Perfusion-Controlled Drug Distribution, 90
 - 4.3.2 Diffusion or Permeability-Controlled Drug Distribution, 93
- 4.4 Distribution of Drugs to the Central Nervous System, 93
- Problems, 96
- References, 98

5 Drug Elimination and Clearance

99

Sara E. Rosenbaum

- 5.1 Introduction, 100
 - 5.1.1 First-Order Elimination, 101
 - 5.1.2 Determinants of the Elimination Rate Constant and the Half-Life, 102
- 5.2 Clearance, 102
 - 5.2.1 Definition and Determinants of Clearance, 102
 - 5.2.2 Total Clearance, Renal Clearance, and Hepatic Clearance, 104
 - 5.2.3 Relationships among Clearance, Volume of Distribution, Elimination Rate Constant, and Half-Life, 105
 - 5.2.4 Primary and Secondary Parameters, 106
 - 5.2.5 Measurement of Total Body Clearance, 106
- 5.3 Renal Clearance, 108
 - 5.3.1 Glomerular Filtration, 109
 - 5.3.2 Tubular Secretion, 110
 - 5.3.3 Tubular Reabsorption, 113
 - 5.3.4 Putting Meaning into the Value of Renal Clearance, 114
 - 5.3.5 Measurement of Renal Clearance, 115
 - 5.3.6 Fraction of the Dose Excreted Unchanged, 118
- 5.4 Hepatic Elimination and Clearance, 119
 - 5.4.1 Phase I and Phase II Metabolism, 120
 - 5.4.2 The Cytochrome P450 Enzyme System, 121
 - 5.4.3 Glucuronidation, 122
 - 5.4.4 Metabolism-Based Drug–Drug Interactions, 122
 - 5.4.5 Hepatic Drug Transporters and Drug–Drug Interactions, 125
 - 5.4.6 Kinetics of Drug Metabolism, 127
 - 5.4.7 Hepatic Clearance and Related Parameters, 128
- Problems, 139
- References, 142

6 Compartmental Models in Pharmacokinetics

145

Sara E. Rosenbaum

- 6.1 Introduction, 146

- 6.2 Expressions for Component Parts of the Dose–Plasma Concentration Relationship, 146
 - 6.2.1 Effective Dose, 146
 - 6.2.2 Rate of Drug Absorption, 147
 - 6.2.3 Rate of Drug Elimination, 148
 - 6.2.4 Rate of Drug Distribution, 148
- 6.3 Putting Everything Together: Compartments and Models, 149
 - 6.3.1 One-Compartment Model, 149
 - 6.3.2 Two-Compartment Model, 150
 - 6.3.3 Three-Compartment Model, 150
- 6.4 Examples of Complete Compartment Models, 152
 - 6.4.1 Intravenous Bolus Injection in a One-Compartment Model with First-Order Elimination, 152
 - 6.4.2 Intravenous Bolus Injection in a Two-Compartment Model with First-Order Elimination, 153
 - 6.4.3 First-Order Absorption in a Two-Compartment Model with First-Order Elimination, 154
- 6.5 Use of Compartmental Models to Study Metabolite Pharmacokinetics, 155
- 6.6 Selecting and Applying Models, 156
- Problems, 157
- Suggested Readings, 157

7 Pharmacokinetics of an Intravenous Bolus Injection in a One-Compartment Model

159

Sara E. Rosenbaum

- 7.1 Introduction, 160
- 7.2 One-Compartment Model, 160
- 7.3 Pharmacokinetic Equations, 162
 - 7.3.1 Basic Equation, 162
 - 7.3.2 Half-Life, 163
 - 7.3.3 Time to Eliminate a Dose, 163
- 7.4 Simulation Exercise, 163
- 7.5 Application of the Model, 165
 - 7.5.1 Predicting Plasma Concentrations, 165
 - 7.5.2 Duration of Action, 166
 - 7.5.3 Value of a Dose to Give a Desired Initial Plasma Concentration, 167
 - 7.5.4 Intravenous Loading Dose, 167
- 7.6 Determination of Pharmacokinetic Parameters Experimentally, 168
 - 7.6.1 Study Design for the Determination of Parameters, 168
 - 7.6.2 Pharmacokinetic Analysis, 169
- 7.7 Pharmacokinetic Analysis in Clinical Practice, 173
- Problems, 174
- Suggested Reading, 176

8 Pharmacokinetics of an Intravenous Bolus Injection in a Two-Compartment Model

177

Sara E. Rosenbaum

- 8.1 Introduction, 178

- 8.2 Tissue and Compartmental Distribution of a Drug, 179
 - 8.2.1 Drug Distribution to the Tissues, 179
 - 8.2.2 Compartmental Distribution of a Drug, 180
- 8.3 Basic Equation, 181
 - 8.3.1 Distribution: A , α , and the Distribution $t_{1/2}$, 182
 - 8.3.2 Elimination: B , β , and the $\beta t_{1/2}$, 182
- 8.4 Relationship Between Macro and Micro Rate Constants, 183
- 8.5 Primary Pharmacokinetic Parameters, 183
 - 8.5.1 Clearance, 184
 - 8.5.2 Distribution Clearance, 184
 - 8.5.3 Volume of Distribution, 186
- 8.6 Simulation Exercise, 188
- 8.7 Determination of the Pharmacokinetic Parameters of the Two-Compartment Model, 191
 - 8.7.1 Determination of Intercepts and Macro Rate Constants, 191
 - 8.7.2 Determination of the Micro Rate Constants: k_{12} , k_{21} , and k_{10} , 193
 - 8.7.3 Determination of the Primary Pharmacokinetic Parameters, 193
- 8.8 Clinical Application of the Two-Compartment Model, 194
 - 8.8.1 Measurement of the Elimination Half-Life in the Postdistribution Phase, 194
 - 8.8.2 Determination of the Loading Dose, 195
 - 8.8.3 Evaluation of a Dose: Monitoring Plasma Concentrations and Patient Response, 197
- Problems, 197
- Suggested Readings, 199

9 Pharmacokinetics of Extravascular Drug Administration

201*Dr. Steven C. Sutton*

- 9.1 Introduction, 202
- 9.2 First-Order Absorption in a One-Compartment Model, 203
 - 9.2.1 Model and Equations, 203
 - 9.2.2 Parameter Determination, 205
 - 9.2.3 Absorption Lag Time, 210
 - 9.2.4 Flip-Flop Model and Sustained-Release Preparations, 212
 - 9.2.5 Determinants of T_{\max} and C_{\max} , 212
- 9.3 Modified Release and Gastric Retention Formulations, 214
 - 9.3.1 Impact of the Stomach, 214
 - 9.3.2 Moisture in the Gastrointestinal Tract, 215
- 9.4 Bioavailability, 215
 - 9.4.1 Bioavailability Parameters, 215
 - 9.4.2 Absolute Bioavailability, 217
 - 9.4.3 Relative Bioavailability, 217
 - 9.4.4 Bioequivalence, 217
 - 9.4.5 Single-Dose Crossover Parallel and Steady-State Study Designs, 219
 - 9.4.6 Example Bioavailability Analysis, 219
- 9.5 *In Vitro-In Vivo* Correlation, 219
 - 9.5.1 Definitions, 219

- 9.5.2 Assumptions, 220
- 9.5.3 Utility, 220
- 9.5.4 Immediate Release IVIVC, 220
- 9.5.5 Modified Release IVIVC, 221
- 9.6 Simulation Exercise, 222
- Problems, 223
- References, 224

10 Introduction to Noncompartmental Analysis 225

Sara E. Rosenbaum

- 10.1 Introduction, 225
- 10.2 Mean Residence Time, 226
- 10.3 Determination of Other Important Pharmacokinetic Parameters, 229
- 10.4 Different Routes of Administration, 231
- 10.5 Application of Noncompartmental Analysis to Clinical Studies, 232
- Problems, 234

11 Pharmacokinetics of Intravenous Infusion in a One-Compartment Model 237

Sara E. Rosenbaum

- 11.1 Introduction, 238
- 11.2 Model and Equations, 239
 - 11.2.1 Basic Equation, 239
 - 11.2.2 Application of the Basic Equation, 241
 - 11.2.3 Simulation Exercise: Part 1, 241
- 11.3 Steady-State Plasma Concentration, 242
 - 11.3.1 Equation for Steady-State Plasma Concentrations, 242
 - 11.3.2 Application of the Equation, 242
 - 11.3.3 Basic Formula Revisited, 243
 - 11.3.4 Factors Controlling Steady-State Plasma Concentration, 243
 - 11.3.5 Time to Steady State, 244
 - 11.3.6 Simulation Exercise: Part 2, 245
- 11.4 Loading Dose, 246
 - 11.4.1 Loading-Dose Equation, 246
 - 11.4.2 Simulation Exercise: Part 3, 248
- 11.5 Termination of Infusion, 248
 - 11.5.1 Equations for Termination Before and After Steady State, 248
 - 11.5.2 Simulation Exercise: Part 4, 249
- 11.6 Individualization of Dosing Regimens, 249
 - 11.6.1 Initial Doses, 249
 - 11.6.2 Monitoring and Individualizing Therapy, 250
- Problems, 252

12 Multiple Intravenous Bolus Injections in the One-Compartment Model 255

Sara E. Rosenbaum

- 12.1 Introduction, 256
- 12.2 Terms and Symbols Used in Multiple-Dosing Equations, 257

- 12.3 Monoexponential Decay During a Dosing Interval, 259
 - 12.3.1 Calculation of Dosing Interval to Give Specific Steady-State Peaks and Troughs, 260
- 12.4 Basic Pharmacokinetic Equations for Multiple Doses, 260
 - 12.4.1 Principle of Superposition, 260
 - 12.4.2 Equations that Apply Before Steady State, 261
- 12.5 Steady State, 262
 - 12.5.1 Steady-State Equations, 263
 - 12.5.2 Average Plasma Concentration at Steady State, 264
 - 12.5.3 Fluctuation, 267
 - 12.5.4 Accumulation, 267
 - 12.5.5 Time to Reach Steady State, 269
 - 12.5.6 Loading Dose, 270
- 12.6 Basic Formula Revisited, 270
- 12.7 Pharmacokinetic-Guided Dosing Regimen Design, 270
 - 12.7.1 General Considerations for Selection of the Dosing Interval, 270
 - 12.7.2 Protocols for Pharmacokinetic-Guided Dosing Regimens, 272
- 12.8 Simulation Exercise, 276
- Problems, 277
- Reference, 278

13 Multiple Intermittent Infusions

279*Sara E. Rosenbaum*

- 13.1 Introduction, 279
- 13.2 Steady-State Equations for Multiple Intermittent Infusions, 281
- 13.3 Monoexponential Decay During a Dosing Interval: Determination of Peaks, Troughs, and Elimination Half-Life, 284
 - 13.3.1 Determination of Half-Life, 284
 - 13.3.2 Determination of Peaks and Troughs, 286
- 13.4 Determination of the Volume of Distribution, 286
- 13.5 Individualization of Dosing Regimens, 289
- 13.6 Simulation, 289
- Problems, 290

14 Multiple Oral Doses

293*Sara E. Rosenbaum*

- 14.1 Introduction, 293
- 14.2 Steady-State Equations, 294
 - 14.2.1 Time to Peak Steady-State Plasma Concentration, 295
 - 14.2.2 Maximum Steady-State Plasma Concentration, 296
 - 14.2.3 Minimum Steady-State Plasma Concentration, 296
 - 14.2.4 Average Steady-State Plasma Concentration, 296
 - 14.2.5 Overall Effect of Absorption Parameters on a Steady-State Dosing Interval, 297
- 14.3 Equations Used Clinically to Individualize Oral Doses, 298
 - 14.3.1 Protocol to Select an Appropriate Equation, 298
- 14.4 Simulation Exercise, 300
- References, 301

15 Nonlinear Pharmacokinetics 303

Sara E. Rosenbaum

- 15.1 Linear Pharmacokinetics, 304
- 15.2 Nonlinear Processes in Absorption, Distribution, Metabolism, and Elimination, 306
- 15.3 Pharmacokinetics of Capacity-Limited Metabolism, 307
 - 15.3.1 Kinetics of Enzymatic Processes, 307
 - 15.3.2 Plasma Concentration–Time Profile, 309
- 15.4 Phenytoin, 310
 - 15.4.1 Basic Equation for Steady State, 311
 - 15.4.2 Estimation of Doses and Plasma Concentrations, 313
 - 15.4.3 Influence of K_m and V_{max} and Factors That Affect These Parameters, 314
 - 15.4.4 Time to Eliminate the Drug, 316
 - 15.4.5 Time to Reach Steady State, 317
 - 15.4.6 Individualization of Doses of Phenytoin, 318
- Problems, 321
- References, 322

16 Introduction to Pharmacogenetics 323

Dr. Daniel Brazeau

- 16.1 Introduction, 324
- 16.2 Genetics Primer, 324
 - 16.2.1 Basic Terminology: Genes, Alleles, Loci, and Polymorphism, 324
 - 16.2.2 Population Genetics: Allele and Genotype Frequencies, 326
 - 16.2.3 Quantitative Genetics and Complex Traits, 327
- 16.3 Pharmacogenetics, 328
 - 16.3.1 Pharmacogenetics of Drug-Metabolizing Enzymes, 330
 - 16.3.2 Pharmacogenetics of Drug Transporters, 333
- 16.4 Genetics and Pharmacodynamics, 334
 - 16.4.1 Drug Target Pharmacogenetics, 334
- 16.5 Summary, 335
- Reference, 335
- Suggested Readings, 335

17 Models Used to Predict Drug–Drug Interactions for Orally Administered Drugs 337

Sara E. Rosenbaum

- 17.1 Introduction, 338
- 17.2 Mathematical Models for Inhibitors and Inducers of Drug Metabolism Based on *In Vitro* Data, 340
 - 17.2.1 Reversible Inhibition, 340
 - 17.2.2 Time-Dependent Inhibition, 341
 - 17.2.3 Induction, 345
- 17.3 Surrogate *In Vivo* Values for the Unbound Concentration of the Perpetrator at the Site of Action, 345
 - 17.3.1 Surrogate Measures of Hepatic Inhibitor and Inducer Concentrations, 346

- 17.3.2 Surrogate Measures of Intestinal Inhibitor and Inducer Concentrations, 346
- 17.4 Models Used to Predict DDIs *In Vivo*, 347
 - 17.4.1 Introduction, 347
 - 17.4.2 Basic Predictive Models: *R* Values, 348
 - 17.4.3 Predictive Models Incorporating Parallel Pathways of Elimination (*fm*), 350
 - 17.4.4 Models Incorporating Intestinal Extraction, 354
 - 17.4.5 Models Combining Multiple Actions of Perpetrators, 358
- 17.5 Predictive Models for Transporter-Based DDIs, 359
 - 17.5.1 Kinetics of Drug Transporters, 359
- 17.6 Application of Physiologically Based Pharmacokinetic Models to DDI Prediction: The Dynamic Approach, 362
- 17.7 Conclusion, 362
- Problems, 363
- References, 364

18 Introduction to Physiologically Based Pharmacokinetic Modeling 367

Sara E. Rosenbaum

- 18.1 Introduction, 368
- 18.2 Components of PBPK Models, 369
- 18.3 Equations for PBPK Models, 369
- 18.4 Building a PBPK Model, 373
- 18.5 Simulations, 377
- 18.6 Estimation of Human Drug-Specific Parameters, 378
 - 18.6.1 Tissue Plasma Partition Coefficient, 379
 - 18.6.2 Volume of Distribution, 379
 - 18.6.3 Clearance, 380
- 18.7 More Detailed PBPK Models, 381
 - 18.7.1 Permeability-Limited Distribution, 381
 - 18.7.2 Drug Transporters, 383
 - 18.7.3 Models for Oral Absorption, 386
 - 18.7.4 Reduced Models, 387
- 18.8 Application of PBPK Models, 387
- References, 388

19 Introduction to Pharmacodynamic Models and Integrated Pharmacokinetic–Pharmacodynamic Models 391

Drs. Diane Mould and Paul Hutson

- 19.1 Introduction, 392
- 19.2 Classic Pharmacodynamic Models Based on Receptor Theory, 393
 - 19.2.1 Receptor Binding, 394
 - 19.2.2 Concentration-Response Models, 395
- 19.3 Direct Effect Pharmacodynamic Models, 402
 - 19.3.1 E_{\max} and Sigmoidal E_{\max} Models, 402
 - 19.3.2 Inhibitory I_{\max} and Sigmoidal I_{\max} Models, 404
 - 19.3.3 Linear Adaptations of the E_{\max} and I_{\max} Model, 404

19.4	Integrated PK–PD Models: Intravenous Bolus Injection in the One-Compartment Mode and the Sigmoidal E_{\max} Model, 406	
19.4.1	Simulation Exercise, 409	
19.5	Pharmacodynamic Drug–Drug Interactions, 410	
19.5.1	Simulation Exercise, 410	
	Problems, 411	
	References, 412	
20	Semimechanistic Pharmacokinetic–Pharmacodynamic Models	413
	<i>Drs. Diane Mould and Paul Hutson</i>	
20.1	Introduction, 414	
20.2	Hysteresis and the Effect Compartment, 416	
20.2.1	Simulation Exercise, 419	
20.3	Physiological Turnover Models and Their Characteristics, 419	
20.3.1	Points of Drug Action, 421	
20.3.2	System Recovery After Change in Baseline Value, 421	
20.4	Indirect Effect Models, 422	
20.4.1	Introduction, 422	
20.4.2	Characteristics of Indirect Effect Drug Responses, 424	
20.4.3	Characteristics of Indirect Effect Models Illustrated Using Model I, 426	
20.5	Other Indirect Effect Models, 432	
20.5.1	Transit Compartment Models, 435	
20.5.2	Model for Hematological Toxicity of Anticancer Drugs, 439	
20.5.3	Alternate Parameterizations of Transit Models, 442	
20.6	Models of Tolerance, 442	
20.6.1	Introduction to Pharmacologic Tolerance, 442	
20.6.2	Counter-Regulatory Force Tolerance Model, 444	
20.6.3	Precursor Pool Model of Tolerance, 447	
20.7	Irreversible Drug Effects, 450	
20.7.1	Application of the Turnover Model to Irreversible Drug Action, 450	
20.8	Disease Progression Models, 452	
20.8.1	Drug Pharmacokinetics, 452	
20.8.2	Pharmacodynamics, 452	
20.8.3	Disease Activity Models, 453	
20.8.4	Disease Progression Models, 453	
	Problems, 459	
	References, 465	
Appendix A	Review of Exponents and Logarithms	469
	<i>Sara E. Rosenbaum</i>	
A.1	Exponents, 469	
A.2	Logarithms: Log and Ln, 470	
A.3	Performing Calculations in the Logarithmic Domain, 471	
A.3.1	Multiplication, 471	
A.3.2	Division, 472	

- A.3.3 Reciprocals, 472
- A.3.4 Exponents, 472
- A.4 Calculations Using Exponential Expressions and Logarithms, 472
- A.5 Decay Function: e^{-kt} , 474
- A.6 Growth Function: $1 - e^{-kt}$, 475
- A.7 Decay Function in Pharmacokinetics, 475
- Problems, 476

Appendix B Rates of Processes **479**

Sara E. Rosenbaum

- B.1 Introduction, 479
- B.2 Order of a Rate Process, 480
- B.3 Zero-Order Processes, 480
 - B.3.1 Equation for Zero-Order Filling, 480
 - B.3.2 Equation for Zero-Order Emptying, 481
 - B.3.3 Time for Zero-Order Emptying to Go to 50% Completion, 481
- B.4 First-Order Processes, 482
 - B.4.1 Equation for a First-Order Process, 482
 - B.4.2 Time for 50% Completion: the Half-Life, 483
- B.5 Comparison of Zero- and First-Order Processes, 484
- B.6 Detailed Example of First-Order Decay in Pharmacokinetics, 484
 - B.6.1 Equations and Semilogarithmic Plots, 484
 - B.6.2 Half-Life, 485
 - B.6.3 Fraction or Percent Completion of a First-Order Process Using First-Order Elimination as an Example, 485
- B.7 Examples of the Application of First-Order Kinetics to Pharmacokinetics, 487

Appendix C Creation of Excel Worksheets for Pharmacokinetic Analysis **489**

Sara E. Rosenbaum

- C.1 Measurement of AUC and Clearance, 489
 - C.1.1 Trapezoidal Rule, 490
 - C.1.2 Excel Spreadsheet to Determine $AUC_{0 \rightarrow \infty}$ and Clearance, 491
- C.2 Analysis of Data from an Intravenous Bolus Injection in a One-Compartment Model, 494
- C.3 Analysis of Data from an Intravenous Bolus Injection in a Two-Compartment Model, 496
- C.4 Analysis of Oral Data in a One-Compartment Model, 498
- C.5 Noncompartmental Analysis of Oral Data, 501

Appendix D Derivation of Equations for Multiple Intravenous Bolus Injections **505**

Sara E. Rosenbaum

- D.1 Assumptions, 505

D.2	Basic Equation for Plasma Concentration After Multiple Intravenous Bolus Injections, 505	
D.3	Steady-State Equations, 508	
Appendix E	Enzyme Kinetics: Michaelis–Menten Equation and Models for Inhibitors and Inducers of Drug Metabolism	509
	<i>Sara E. Rosenbaum and Roberta S. King</i>	
E.1	Kinetics of Drug Metabolism: The Michaelis–Menten Model, 510	
E.1.1	Overview, 510	
E.1.2	Assumptions for Validity of Michaelis–Menten Model, 510	
E.1.3	K_m and V_{max} , 511	
E.1.4	Derivation of the Michaelis–Menten Equation, 511	
E.1.5	Summary, Practical Considerations, and Interpretations, 513	
E.1.6	Relationship Between Intrinsic Clearance and the Michaelis–Menten Parameters, 514	
E.2	Effect of Perpetrators of DDI on Enzyme Kinetics and Intrinsic Clearance, 515	
E.2.1	Reversible Inhibition, 515	
E.2.2	Time-Dependent Inhibition, 518	
E.2.3	Enzyme Induction, 524	
	References, 526	
Appendix F	Summary of the Properties of the Fictitious Drugs Used in the Text	527
	<i>Sara E. Rosenbaum</i>	
Appendix G	Computer Simulation Models	529
	<i>Sara E. Rosenbaum</i>	
	Glossary of Terms	531
	Index	537

PREFACE

The goal of the second edition of Basic Pharmacokinetics and Pharmacodynamics is to update and strengthen existing chapters of the book and to add additional chapters in response to recent trends in the application of pharmacokinetics and pharmacodynamics in clinical practice and pharmaceutical research.

Notable areas of update and expansion include both the text and the interactive computer models associated with drug transporters and hepatic clearance. Additionally, the chapters on drug absorption/bioavailability and pharmacodynamics have been updated, expanded and strengthened to reflect the importance of these topics and the need to cover the material both comprehensively and in a manner compatible with their present application. I felt that these areas would be most effectively strengthened by experts in each of the fields. To this end, I am delighted that Dr. Steven Sutton, who has had extensive experience as a researcher in the pharmaceutical industry and as an educator at the College of Pharmacy, University of New England, agreed to take over Chapters 3 and 9 that cover drug absorption and bioavailability. I am also delighted that Drs. Diane Mould and Paul Hutson agreed to revamp and expand the chapters on pharmacodynamics (Chapters 19 and 20). Dr. Mould of Projections Research Inc is a well-known pharmacokinetic and pharmacodynamic modeler, who has extensive experience in the application of pharmacodynamic models. Dr. Hutson from University of Wisconsin, School of Pharmacy, is similarly experienced and was able to provide an academic perspective to the overhaul of this material.

Owing to the increasing prominence of personalized and precision medicine, it has become important that clinical pharmacists and researchers in pharmaceutical fields have a basic knowledge of pharmacogenomics. Dr. Daniel Brazeau, an experienced educator and researcher in this area from the College of Pharmacy, University of New England, graciously agreed to write an introductory chapter on pharmacogenetics for the second edition. In response to the increasing use and diverse application of physiologically based pharmacokinetic (PBPK) modeling that has occurred over the last 15 years, it has become essential for modern students of pharmacokinetics to have a foundation in this topic. Chapter 18 introduces PBPK models and describes how they are built and applied. The third new chapter in the second edition presents the predictive models used to evaluate drug–drug

interaction (DDI) risk using *in vitro* data. These models are used increasingly by pharmaceutical companies and drug regulators to try to reduce the large health risks and costs posed by DDIs. While not all readers of the book will need to apply these models professionally, an understanding of this topic will allow students to better understand and appreciate the mechanism, characteristics, and varied outcome of DDIs. Finally, in order to provide interested students with a foundation to this latter chapter, the second edition includes an appendix on basic enzyme kinetics and the mathematical basis of the predictive models. My colleague at the College of Pharmacy, Dr. Roberta King, an expert in drug metabolism, collaborated in the preparation of this material. Each of the new chapters is supported by new interactive computer models.

It is hoped that the second edition of this textbook provides a comprehensive and thorough presentation of all essential topics in the contemporary application of pharmacokinetics and pharmacodynamics. While not all chapters will be necessary for the immediate needs of all audiences, collectively the book should serve as a valuable reference for the future.

I would like to thank the many scientists who generously gave of their time and provided me with information and input in many areas. I would especially like to thank Dr. Karthik Venkatakrishnan for his valuable input on the chapter on predictive models for DDIs. I would also like to thank and recognize the wonderful work of Pragati Nahar who prepared the custom color figures in the book, including the figure used on the cover. I would also like to thank many undergraduate and graduate students at URI who helped in a variety of ways especially Jamie Chung who provided valuable support for the preparation of the materials, and Benjamin Barlock and Rohitash Jamwal for their input in the creation of the simulation models. Finally, I would like to thank Jonathan Rose at Wiley for his patience, understanding, and responsiveness in the preparation of this edition.

CONTRIBUTORS

Daniel Brazeau Daniel Brazeau is a Research Associate Professor at the University of New England. He holds joint appointments in the Department of Pharmaceutical Sciences in the College of Pharmacy and Department of Biomedical Sciences in the College of Osteopathic Medicine. Dr. Brazeau is a Director of UNE's Genomics Core, a research training core providing the expertise, technologies and most importantly, training support for faculty and students. He received his B.S. and M.S. in Biology from the University of Toledo and earned his Ph.D. in Biological Sciences (1989) from the University at Buffalo. After completing postdoctoral training in population genetics at the University of Houston, he was a Research Assistant Professor in the Department of Zoology at the University of Florida and Director of the University of Florida's Genetic Analysis Laboratory in the Interdisciplinary Research Center for Biotechnology. For 10 years prior to joining UNE, he was a Research Associate Professor in the Department of Pharmaceutical Sciences at the University at Buffalo and Director of the University at Buffalo's Pharmaceutical Genetics Laboratory. Dr. Brazeau's research interests involve the areas of population molecular genetics and genomics. He teaches courses in molecular genetics methodologies and a required course in pharmacogenomics for graduate and pharmacy professional students. Dr. Brazeau is also a participating scientist in the National Science Foundation's Geneticist-Educator Network Alliances (GENA) working with high school science teachers to incorporate genetics into the classroom.

Paul Hutson Paul Hutson, whose baccalaureate and master's degrees are in biochemistry and chemistry, respectively, completed an oncology/pharmacokinetics fellowship at St. Jude Children's Research Hospital in Memphis. He was a Faculty Member at the University of Illinois for 5 years before moving to the University of Wisconsin School of Pharmacy in Madison in 1988. He now practices pharmacy with the oncology and palliative care group at the UW Hospital and Clinics and is an Associate Member of the UW Carbone Cancer Center. His three course offerings at the School of Pharmacy are Clinical Pharmacokinetics, Pediatric Pharmacotherapy, and Dietary Supplements, and he supervises an Advanced Pharmacy Practice Experience (APPE) in basic pharmacometrics. Dr. Hutson

provides pharmacometric modeling services to the pharmaceutical industry and to University of Wisconsin—Madison investigators through its CTSA-funded Institute for Clinical and Translational Research.

Roberta S. King Roberta S. King is an Associate Professor at the University of Rhode Island, College of Pharmacy. Her research expertise is in metabolism and enzymology focusing on individual variation in activity of the drug-metabolizing enzymes. She teaches Drug Metabolism and Structure-based Drug Design.

Dr. Mould Dr. Mould obtained her bachelors degree at Stevens Institute of Technology in 1984 in Chemistry and Chemical Biology. She received her Ph.D. in Pharmaceutics and Pharmaceutical Chemistry at The Ohio State University (OSU) in 1989. She spent 26 years as a pharmacokineticist in industry where she specialized in population pharmacokinetic/pharmacodynamic modeling and was an Associate Research Professor at Georgetown University. She has conducted population PK/PD analyses of hematopoietic agents, monoclonal antibodies, anticancer and antiviral agents, antipsychotic, cardiovascular, and sedative/hypnotic agents. Dr Mould is involved in clinical trial simulation and optimal study design in drug development. She was a member of the Scientific Advisory Group for PharSight, where she assisted in development of clinical trial simulation software.

Currently, Dr Mould is President of Projections Research Inc., a consulting company offering pharmacokinetic and pharmacometric services. She is also the founder of iDose LLC, a company that develops systems to individualize doses of drugs that are difficult to manage. She has published 62 peer-reviewed articles, 16 book chapters, made 97 national and international presentations, and presented six podium sessions on advanced modeling and simulation approaches. Dr Mould has authored 97 posters at both national and international meetings. She is an Adjunct Professor at the University of Rhode Island (URI), OSU, and the University of Florida, and teaches an annual class on disease progression modeling at the National Institutes of Health. Dr Mould taught nine courses (OSU, URI, and SUNY Buffalo) on specialized aspects of population pharmacokinetic and dynamic modeling. She is a member of the editorial board for Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology and Therapeutics, and Clinical Pharmacology and Therapeutics Pharmacometrics and Systems Pharmacology. Dr. Mould is a member of the Board of Regents for the American College of Clinical Pharmacology and is a Chairman of the Publications committee for this organization. She is a Fellow of the American College of Clinical Pharmacology and the American Association of Pharmaceutical Sciences.

Steven C. Sutton Steven (Steev) C. Sutton, B.S. Pharmacy, Ph.D., University of New England, Portland, Maine Dr. Sutton is an Associate Professor and Chair of Pharmaceutics, College of Pharmacy, University of New England in Portland, Maine. He received his B.S. in Pharmacy from Massachusetts College of Pharmacy and a Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo, New York. Dr Sutton began his career in the pharmaceutical industry working for CIBA-Geigy in Ardsley, NY (now Novartis), for INTERx in Lawrence, KS (then a part of Merck), and for Pfizer in Groton, CT, before embarking in a second career—that of academia—at the University of New England College of Pharmacy in Portland in 2009. Dr. Sutton founded the AAPS Oral Absorption Focus Group and in 2003, he became a Fellow of the AAPS. His research interests include predicting active pharmaceutical ingredient concentration–time profile in human after oral administration from chemical structure, modeling, and simulation of oral absorption of low permeability and/or low aqueous soluble compounds, *in vitro*—*in vivo* correlation of orally

administered controlled release dosage forms, species differences in gastrointestinal (GI) physiology, and transport of nanoparticles across the GI epithelium. Dr. Sutton has authored or coauthored over 120 book chapters, abstracts of work in progress, invited presentations, and patents.

1

INTRODUCTION TO PHARMACOKINETICS AND PHARMACODYNAMICS

SARA E. ROSENBAUM

- 1.1 Introduction: Drugs and Doses
 - 1.2 Introduction to Pharmacodynamics
 - 1.2.1 Drug Effects at the Site of Action
 - 1.2.1.1 Interaction of a Drug with Its Receptor
 - 1.2.1.2 Postreceptor Events
 - 1.2.2 Agonists, Antagonists, and Concentration–Response Relationships
 - 1.3 Introduction to Pharmacokinetics
 - 1.3.1 Plasma Concentration of Drugs
 - 1.3.2 Processes in Pharmacokinetics
 - 1.4 Dose–Response Relationships
 - 1.5 Therapeutic Range
 - 1.5.1 Determination of the Therapeutic Range
 - 1.6 Summary
- Reference

Objectives

The material in this chapter will enable the reader to:

1. Define pharmacodynamics and pharmacokinetics
2. Understand the processes that control the dose–response relationship
3. Gain a general appreciation of how mathematical expressions in pharmacodynamics and pharmacokinetics can be used for the rational determination of optimum dosing regimens

1.1 INTRODUCTION: DRUGS AND DOSES

Drugs may be defined as chemicals that alter physiological or biochemical processes in the body in a manner that makes them useful in the treatment, prevention, or cure of diseases. Based on this definition, any useful drug must affect body physiology or biochemistry. By extension, any useful drug must, if used inappropriately, possess the ability to do harm. Drug action begins with administration of the drug (input) and concludes with the biological response (output, which can be a beneficial and/or an adverse effect). The inputs (dose, frequency of administration, and route of administration) must be selected carefully to optimize the onset, intensity, and duration of therapeutic effects for a particular disease condition. At the same time, the inputs selected must minimize any harmful effects of drugs.

The design of optimum dosing regimens requires a complete understanding of the processes and steps that translate the input into the output. It also requires an understanding of how the input–output relationship may be influenced by individual patient characteristics that may exist at the very beginning of therapy, as well as conditions that may arise during the course of drug therapy. These will include the age and weight of the patient, the presence of other diseases, genetic factors, concurrent medications, and changes in the disease being treated over time.

The material presented in this book will address and explain why, as shown in Table 1.1, there is such tremendous variability in the value of drug doses and dosing frequencies among therapeutic drugs. Additionally, it will address why different routes of administration are used for different drugs and different indications (Table 1.1).

The steps between drug input and the emergence of the response can be broken down into two phases: pharmacokinetic and pharmacodynamic. The *pharmacokinetic phase* encompasses all the events between the administration of a dose and the achievement of drug concentrations throughout the body. The *pharmacodynamic phase* encompasses all the events between the arrival of the drug at its site of action and the onset, magnitude, and duration of the biological response (Figure 1.1). The rational design of optimum dosing regimens must be based on a thorough understanding of these two phases and will, ideally, include the development of one or more mathematical expressions for the relationship between dose and the time course of drug response.

Optimum drug administration is important not only for ensuring good patient outcomes in clinical practice, but also in the design of clinical trials during drug development. The

TABLE 1.1 Examples of Common Daily Doses and Dosing Intervals

Drug	Daily Dose (mg)	Dose Frequency (h)	Route
Calcium carbonate	3000	2	Oral
Ibuprofen	1600	6	Oral
Vancomycin (for MRSA ^a)	2000	12	Intravenous
Amoxicillin	750	8	Oral
Vancomycin (for pseudomembranous colitis)	1000	6	Oral
Atenolol	100	24	Oral
Fluoxetine	20	24	Oral
Ramipril	10	12	Oral
Digoxin	0.250	24	Oral
Chloroquine	300	Weekly	Oral

^aMethicillin-resistant *Staphylococcus aureus*.




FIGURE 1.1 The two phases of drug action. The pharmacokinetic phase is concerned with the relationship between the value of the dose administered and the value of the drug concentrations achieved in the body; the pharmacodynamic phase is concerned with the relationship between drug concentrations at the site of action and the onset, intensity, and duration of drug response.

cost of drug research and development is enormous, so it is critical that all drug candidates selected for human trials are evaluated in the most efficient, cost-effective manner possible.

The application of pharmacokinetic and pharmacodynamic principles to this process has been shown to enhance the selection of optimum doses and optimum designs of phase II clinical trials.

1.2 INTRODUCTION TO PHARMACODYNAMICS

Pharmaco- comes from the Greek word for “drug,” *pharmakon*, and *dynamics* means “of or relating to variation of intensity.” *Pharmacodynamics (PD)* is the study of the magnitude of drug response. In particular, it is the study of the onset, intensity, and duration of drug response and how these are related to the concentration of a drug at its site of action. An overview of some basic drug terminology and the drug response–concentration relationship is provided below.

1.2.1 Drug Effects at the Site of Action

Note that although some references and textbooks distinguish the terms drug *effect* and drug *response*, this distinction has not been adopted universally. In this book, *effect* and *response* are used interchangeably.

1.2.1.1 Interaction of a Drug with Its Receptor

Drug response is initiated by a chemical interaction between a drug and a special binding site on a macromolecule in a tissue. This macromolecule is known as a drug *receptor*. The drug–receptor interaction results in a conformational change in the receptor, which results in the generation of a stimulus that ultimately leads to a biochemical or physiological response (Figure 1.2). Most receptors (over 95%) are proteins; however, other types of receptors exist such as the DNA receptors of the alkylating agents used in cancer chemotherapy. The drug–receptor interaction involves chemical bonding, which is usually reversible in nature and can be expressed using the law of mass action (Figure 1.2). Thus, at the site of action, the drug binds to its receptor and equilibrium is established between the bound and the unbound drug. As the drug is eliminated from the body and removed from its site of action, it dissociates from the receptor, which is left unchanged, and the response dissipates.




FIGURE 1.2 Drug–receptor interaction. Here, AG signifies a drug agonist, $[D]$ is the free drug concentration (not bound to the receptor), R is the concentration of free receptors, $[RD]$ is the concentration of the drug–receptor complex, and k_{on} and k_{off} are the rate constants for the forward and backward processes, respectively.

In contrast, a few drugs form *irreversible* covalent bonds with their receptors. For example, aspirin inhibits platelet aggregation by inhibiting the formation of thromboxane in the platelets. It accomplishes this by binding covalently to and blocking the catalytic activity of cyclooxygenase, the enzyme that produces thromboxane. The effect of a single dose of aspirin will persist long after the drug has been removed from its site of action and will continue until new cyclooxygenase molecules are synthesized, which can then resume the production of thromboxane. Other examples of drugs that bind irreversibly to their receptors include the alkylating agents mentioned above and proton pump inhibitors, such as omeprazole, which block the secretion of gastric acid by binding irreversibly to the H^+ , K^+ -ATPase pumps of parietal cells.

The drug–receptor interaction is highly dependent on the chemical structure of both the drug and the receptor and, therefore, small changes in the structure of the drug can reduce or destroy activity. For example, the drug–receptor interaction can distinguish between the *R*- and *S*-isomers of drugs that have chiral carbon atoms. Usually, one isomer is much more active than the other. The *S*-isomer of warfarin, for example, is two to five times more active than the *R*-isomer. The development and promotion of *S*-omeprazole (Nexium) is based on the premise that the *S*-isomer has the higher affinity for the binding site and thus offers therapeutic advantages over preparations containing racemic mixtures (equal quantities of each isomer) of omeprazole, such as Prilosec and its generic equivalents.

Receptors are assumed to exist for all active endogenous compounds (*natural ligands*) such as neurotransmitters and hormones. The interaction between natural ligands and their receptors controls and/or regulates physiological and biochemical processes in the body. In most cases, drugs mimic or antagonize the actions of endogenous ligands by interacting with their cognate receptors. For example, epinephrine is a natural ligand that interacts with β_2 -adrenergic receptors in bronchial smooth muscle to bring about bronchial dilation. Albuterol, a drug, also interacts with this receptor to produce bronchial dilation. Acetylcholine transmits signals through a synapse by interacting with its nicotinic receptor found on postsynaptic neuronal membranes. This interaction, which is mimicked by the drug nicotine, results in the production of a response called an action potential.

It should be noted that there are a few drugs that do not act on receptors but that exert their action by bringing about *physicochemical changes* in the body. For example, conventional